article thumbnail

Big pharma companies team up to increase diversity in genome data

Outsourcing Pharma

The pharma giants AbbVie, Amgen, AstraZeneca, Bayer and Merck have been revealed as founding members of the Alliance for Genomic Discovery (AGD), a project aiming to accelerate drug development by collecting genomic data from underrepresented populations.

Genome 54
article thumbnail

New podcast on the future for genomics and big data

Drug Discovery World

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, and “ Why a recent advancement is a giant leap for human genomics ”. Listen here: The post New podcast on the future for genomics and big data appeared first on Drug Discovery World (DDW).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What lies in the future for genomics and big data?

Drug Discovery World

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, and “ Why a recent advancement is a giant leap for human genomics ”. Listen here: The post What lies in the future for genomics and big data? They are called “ What’s the next step in big data and AI? ”

article thumbnail

Sophia Genetics launches AI tool to find COVID-19 ‘unknowns’

pharmaphorum

The data mining tool will be used to try to unearth some of the many unknowns with the virus, using next-generation sequencing (NGS) to see how the genome of SARS-CoV-2 changes over time, along with patient genetic information, results of lung and CT scans, and other clinical data.

Genetics 136
article thumbnail

Cybersecurity in pharma: Securing the future

Pharmaceutical Technology

Pharma companies around the world have also faced similar threats , some of which have impacted national security and public health. There is also a debate as to how genomic information should be protected,” he adds. How we handle these questions from a technological and regulatory perspective is really critical.”

article thumbnail

Drug development and working with specialised Rare Disease networks

pharmaphorum

In a recent webinar held by pharmaphorum, in partnership with IQVIA, a discussion was held looking at how to make academic and commercial medical research more efficient, while also looking at the opportunity of genomic data to bring benefits to patients and healthcare systems. The potential to leverage genomic data.

article thumbnail

Gene editing: beyond the hype

pharmaphorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. The genomic medicine journey.